Press Releases
-
Jun 5, 2013
SAN RAFAEL, Calif., June 5, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it has initiated the Phase 3 program for PEG-PAL (PEGylated recombinant...
-
Jun 3, 2013Phase 3 Trial in Metastatic gBRCA Breast Cancer Planned to Start in Q4 2013
SAN RAFAEL, Calif., June 3, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced an update on the ongoing Phase 1/2 study for its poly ADP-ribose polymerase (PARP)...
-
May 30, 2013Vimizim Designated for Accelerated Assessment by the EMA
SAN RAFAEL, Calif., May 30, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization...
-
May 30, 2013PDUFA Action Date Extended to February 28, 2014
SAN RAFAEL, Calif., May 30, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the...
-
May 20, 2013
SAN RAFAEL, Calif., May 20, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that on May 15, 2013, the compensation committee of BioMarin's board of directors...
-
May 16, 2013Phase 3 Trial in gBRCA Breast Cancer Planned for 4Q 2013
SAN RAFAEL, Calif., May 16, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that data from its ongoing Phase 1/2 trial for BMN-673 for genetically-defined...
-
Apr 25, 2013Total Revenue Continues Steady Growth of 10 Percent; Progress on All Aspects of the Business
Financial Highlights ($ in millions, except per share data, unaudited) Q1 2013 Q1 2012 Percent Change Total BioMarin Revenue $ 127.9 $ 116.6 9.7% Total Net Product Revenue 127.3 116.2 9.6%...
-
Apr 24, 2013
SAN RAFAEL, Calif., April 24, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the submission of a Marketing Authorization Application (MAA) to the European...
-
Apr 18, 2013
SAN RAFAEL, Calif., April 18, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that on April 15, 2013, the compensation committee of BioMarin's board of...
-
Apr 1, 2013
SAN RAFAEL, Calif., April 1, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the submission of a Biologics License Application (BLA) to the U.S. Food and Drug...
-
Apr 1, 2013
SAN RAFAEL, Calif., April 1, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it has submitted a Clinical Trial Application (CTA) with the Medicines and...
-
Mar 25, 2013
SAN RAFAEL, Calif., March 25, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that an additional six holders of its 1.875% Convertible Senior Subordinated Notes...
-
Mar 19, 2013
NOVATO, Calif., March 19, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that on March 15, 2013, the compensation committee of BioMarin's board of directors...
-
Mar 19, 2013BMN-701 Meaningfully Improves Respiratory Endpoints
SAN RAFAEL, Calif., March 19, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today results from POM-001, the Phase 1/2 trial for BMN-701, a fusion protein of...
-
Mar 18, 2013
SAN RAFAEL, Calif., March 18, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that seven holders of its 1.875% Convertible Senior Subordinated Notes due 2017...
-
Feb 21, 2013
SAN RAFAEL, Calif., Feb. 21, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it has licensed a Factor VIII gene therapy program for hemophilia A from...
-
Feb 21, 2013Total Revenue in 2012 Exceeds $500 Million
Financial Highlights ($ in millions, except per share data, unaudited) FY 2012 FY 2011 Percent Change Total BioMarin Revenue $ 500.7 $ 441.4 13.4% Total Net Product Revenue 496.5 437.6 13.5%...
-
Feb 20, 2013
SAN RAFAEL, Calif., Feb. 20, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that on February 15, 2013, the compensation committee of BioMarin's board of...
-
Feb 19, 2013
SAN RAFAEL, Calif., Feb. 19, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today results from the PKU-016 ASCEND study, the largest randomized controlled trial...
-
Feb 11, 2013Presentations at WORLD Symposium: Vimizim Phase 3 Results and BMN-701 Phase 1/2 Patient Demographics
SAN RAFAEL, Calif., Feb. 11, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that the following presentations will be featured at the 9th Annual WORLD Symposium...
-
Jan 18, 2013
SAN RAFAEL, Calif., Jan. 18, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that on January 15, 2013, the compensation committee of BioMarin's board of...
-
Jan 7, 2013Lead Program Focused on the Oral Treatment of MPS III
SAN RAFAEL, Calif., Jan. 7, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it has acquired Zacharon Pharmaceuticals, a private biotechnology company based...
-
Dec 21, 2012
SAN RAFAEL, Calif., Dec. 21, 2012 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that on December 18, 2012, the compensation committee of BioMarin's board of...
-
Nov 19, 2012
NOVATO, Calif., Nov. 19, 2012 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that on November 15, 2012, the compensation committee of BioMarin's board of directors...
-
Nov 5, 2012Company Plans to Submit Marketing Applications Starting in 1Q 2013
SAN RAFAEL, Calif., Nov. 5, 2012 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that the pivotal Phase 3 study of GALNS met the primary endpoint of change in...
-
Oct 25, 2012Steady Commercial Growth Supports Advancing Pipeline
Financial Highlights ($ in millions, except per share data, unaudited) Q3 2012 Q3 2011 Percent Change Total BioMarin Revenue $ 128.1 $ 113.4 13.0% Total Net Product Revenue 126.3 112.9 11.9%...
-
Sep 26, 2012Phase 2 Trial Expected to Start in Mid-2013
NOVATO, Calif. , Sept. 26, 2012 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the completion of a Phase 1 study for BMN-111, an analog of C-type Natriuretic...
-
Sep 26, 2012Preliminary Phase 2 Results Indicate Convenient and Accelerated Dosing Regimen Identified
NOVATO, Calif., Sept. 26, 2012 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today preliminary results from the Phase 2 program of PEG-PAL (PEGylated recombinant...
-
Sep 5, 2012Stephen Aselage to Leave the Company
NOVATO, Calif. , Sept. 5, 2012 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Jeff Ajer , the current Vice President, Commercial Operations, the Americas ,...
-
Aug 1, 2012Strong Commercial Performance Supporting Development of Five New Chemical Entities With Multiple Key Clinical Readouts by the End of 2012 Conference Call and Webcast to be Held Today at 5:00 p.m. ET
Financial Highlights ($ in millions, except per share data, unaudited) Item Q2 2012 Q2 2011 Percent Change Total BioMarin Revenue $ 124.0 $ 110.6 12.1% Total Net Product Revenue 123.0 109.6 12.2%...
-
Jul 25, 2012
NOVATO, Calif. , July 25, 2012 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that on July 16, 2012 , the compensation committee of BioMarin's board of directors...
-
May 31, 2012
NOVATO, Calif., May 31, 2012 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced the pricing of an underwritten public offering of 6,500,000 shares of its common stock....
-
May 30, 2012
NOVATO, Calif. , May 30, 2012 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that it is offering to sell 6,500,000 shares of its common stock in an underwritten...
-
May 30, 2012
NOVATO, Calif., May 30, 2012 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that it has granted stock options, time-based restricted stock units and...
-
May 8, 2012
NOVATO, Calif., May 8, 2012 (GlobeNewswire via COMTEX) --BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the appointment of Dan Spiegelman as Executive Vice President and Chief...
-
Apr 26, 2012
Financial Highlights ($ in millions, except per share data, unaudited) Item 1Q 2012 1Q 2011 Comparison Total BioMarin Revenue $116.6 6.6% increase Total Net Product Revenue $116.2 6.6% increase...
-
Mar 8, 2012Largest Phase 3 ERT Study to Date in a Lysosomal Storage Disease Results Expected in the Fourth Quarter of 2012
NOVATO, Calif. , March 8, 2012 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that enrollment is complete for the pivotal Phase 3 trial for N-acetylgalactosamine...
-
Feb 21, 2012CFO Transition Planned Through 2012
NOVATO, Calif. , Feb. 21, 2012 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that Jeffrey Cooper , Senior Vice President and Chief Financial Officer, plans to...
-
Feb 16, 2012
NOVATO, Calif. , Feb. 16, 2012 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the initiation of a Phase 1 study in healthy volunteers for BMN-111, an analog of...
-
Feb 16, 2012
Financial Highlights ($ in millions, except per share data, unaudited) Item FY 2011 FY 2010 Comparison Total BioMarin Revenue $441.4 17.3% increase Total Net Product Revenue $437.6 18.4% increase...
-
Jan 3, 2012
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the J.P. Morgan Healthcare Conference...
-
Jan 3, 2012
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that the Investigational New Drug (IND) application for BMN-111, an analog of C-type Natriuretic Peptide (CNP), for achondroplasia is...
-
Dec 19, 2011Novato, CA Expansion Doubles Current Capacity to Support up to a Billion Dollars in Revenue
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval for the...
-
Dec 8, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today hosted a Research and Development Day where members of the company's management team and industry experts provided an update on BioMarin's product...
-
Nov 30, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that it has completed the buy back of certain intellectual property from SA Pathology, a unit of the Central Adelaide Local Health...
-
Nov 29, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced the initiation of a Phase 2 study for GALNS (N-acetylgalactosamine 6-sulfatase) in patients under five years of age with...
-
Nov 28, 2011Novato, CA Expansion Doubles Current Capacity to Support up to a Billion Dollars in Revenue
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for the manufacturing facility expansion in Novato, CA....
-
Nov 17, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) will host a Research and Development Day for the investment community on Thursday, December 8, 2011 from 8:00 a.m. to 12:00 p.m. at the Four Seasons...
-
Nov 3, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Dan Maher, Senior Vice President of Product Development at BioMarin, will present a company update at the Credit Suisse Healthcare...
-
Oct 27, 2011Pipeline to be Highlighted at R&D Day on December 8th; Many Key Clinical Milestones in the Coming Year
Financial Highlights ($ in millions, except per share data, unaudited) Item Q3 2011 Q3 2010 Comparison Total BioMarin Revenue $113.4 16.0% increase Total Net Product Revenue $112.9 16.9% increase...
-
Sep 29, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, October 27, at...
-
Sep 20, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Jefferies Global Healthcare...
-
Sep 13, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Steve Aselage, Chief Business Officer of BioMarin, will present a company update at the UBS Global Life Sciences Conference in New...
-
Sep 7, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Hank Fuchs, M.D., Chief Medical Officer of BioMarin, will present a company update at the Morgan Stanley Global Healthcare...
-
Aug 30, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jeffrey Cooper, Chief Financial Officer of BioMarin, will present a company update at the Baird Health Care Conference in New York...
-
Aug 9, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Wedbush Life Sciences Conference...
-
Jul 28, 2011Ongoing study suggests GALNS sustains improvements in endurance and respiratory function for at least 2 years
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced an update on the GALNS Phase 1/2 extension study (MOR-100) in which patients have continued treatment on an ongoing basis. Patients...
-
Jul 28, 2011Strong Commercial Performance Drives 20% Year Over Year Growth in Total Revenue Conference Call and Webcast to Be Held Today at 5:00 p.m. ET
Financial Highlights ($ in millions, except per share data, unaudited) Item Q2 2011 Q2 2010 Comparison Total BioMarin Revenue $110.6 20.2% increase Total Net Product Revenue $109.6 21.0% increase...
-
Jul 14, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced the initiation of a Phase 1 trial for BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor, for the treatment of patients with...
-
Jun 30, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, July 28, at 5:00...
-
Jun 23, 2011New facility will greatly expand manufacturing capacity and diversify risk
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that it has entered into a definitive agreement to acquire a bulk biologics manufacturing plant from Pfizer, located in Shanbally, Cork,...
-
Jun 8, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Dan Maher, Senior Vice President of Product Development of BioMarin, will present a company update at the William Blair Growth...
-
Jun 7, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that the first patient has been dosed in the Phase 3 trial for amifampridine phosphate (3,4-diaminopyridine phosphate) for the treatment...
-
May 31, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jeffrey Cooper, Chief Financial Officer of BioMarin, will present a company update at the Jefferies Global Healthcare Conference in...
-
May 18, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the UBS Global Specialty...
-
May 3, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Bank of America Merrill Lynch...
-
Apr 28, 2011Net Product Revenue Growth of 30% in the First Quarter of 2011; Improved Top and Bottom-Line Guidance
Financial Highlights ($ in millions, except per share data, unaudited) Item Q1 2011 Q1 2010 Comparison Total BioMarin Revenue $109.5 28.8% increase Total Net Product Revenue $109.1 29.7% increase...
-
Apr 26, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Steve Aselage, Chief Business Officer of BioMarin, will present a company update at the Deutsche Bank Healthcare Conference in...
-
Mar 28, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, April 28, at 5:00...
-
Mar 18, 2011Additional posters at ACMG describe ongoing studies designed to further examine the use of KUVAN® for PKU, with endpoints of neuropsychiatric effects and long-term safety in children
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today preliminary results from ADAPT (A Diversified Approach for PKU Treatment) in an abstract (Abstract #91, Mental Health Screening in...
-
Mar 8, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Barclays Global Healthcare...
-
Mar 1, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Dan Maher, Senior Vice President of Product Development of BioMarin, will present a company update at the Cowen Health Care...
-
Feb 22, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Joshua Grass, Vice President of Corporate and Business Development of BioMarin, will present a company update at the Citi Global...
-
Feb 17, 2011Net Product Revenue Growth of 17% in 2010; Late Stage Clinical Pipeline Advancing
Financial Highlights ($ in millions, except per share data, unaudited) Item FY 2010 FY 2009 Comparison Total BioMarin Revenue $376.3 15.9% increase Total Net Product Revenue $369.7 17.1% increase...
-
Feb 1, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that it has initiated a pivotal Phase 3 trial for N-acetylgalactosamine 6-sulfatase (GALNS or BMN 110), intended for the treatment of...
-
Jan 24, 2011Conference Call and Webcast on Thursday, February 17 at 5:00 p.m. ET
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, February 17, at...
-
Jan 19, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that it has initiated a Phase 1/2 trial for BMN 701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase...
-
Jan 11, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced the initiation of a Phase 1/2 trial for BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor in development for the treatment of...
-
Jan 5, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the J.P. Morgan 29th Annual Healthcare...
-
Dec 14, 2010
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK has completed review of the Clinical Trial Application...
-
Dec 7, 2010
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Joshua Grass, Vice President of Corporate and Business Development of BioMarin, will present a company update at the Deutsche Bank...
-
Dec 2, 2010
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK has completed review of the Clinical Trial Application...
-
Nov 29, 2010
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jeffrey Cooper, Chief Financial Officer of BioMarin, will present a company update at the Piper Jaffray Healthcare Conference in...
-
Nov 9, 2010
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that six holders of its 2.50% Convertible Senior Subordinated Notes due 2013 have agreed to exchange $87.0 million in aggregate...
-
Oct 28, 2010Strong Performance in Commercial Business; Best Quarter Ever for Net Product Revenue
Financial Highlights ($ in millions, except per share data, unaudited) Item Q3 2010 Q3 2009 Comparison Total BioMarin Revenue $97.8 21.0% increase Total Net Product Revenue $96.6 23.2% increase...
-
Oct 19, 2010
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced its program for BMN-111, a peptide therapeutic for the treatment of achondroplasia. BioMarin plans to file an IND in the fourth quarter...
-
Oct 14, 2010
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) will host a Research and Development Day for the investment community on Tuesday, October 19, 2010 from 8:00 a.m. to 12:00 p.m. at the St. Regis Hotel...
-
Oct 7, 2010
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, October 28, at...
-
Oct 5, 2010
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) will host a Research and Development Day for the investment community on Tuesday, October 19, 2010 from 8:00 a.m. to 12:00 p.m. at the St. Regis Hotel...
-
Sep 23, 2010
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today the appointment of William D. Young and Kenneth M. Bate to its Board of Directors. "We are extremely pleased to welcome William Young...
-
Sep 14, 2010
BioMarin Pharmaceutical Inc. today announced that Joshua Grass, Vice President, Corporate and Business Development of BioMarin, will present a company update at the UBS Global Life Sciences...
-
Sep 9, 2010
BioMarin Pharmaceutical Inc. today announced that Dan Maher, Senior Vice President of Product Development of BioMarin, will present a company update at the Stifel Nicolaus Healthcare Conference in...
-
Sep 8, 2010
BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Robert W. Baird Healthcare Conference in New York...
-
Sep 7, 2010
BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Morgan Stanley Global Healthcare Conference in...
-
Sep 1, 2010Kuvan Patients Show Improvements in Neurocognitive Functioning, Mood and Behavior
BioMarin Pharmaceutical Inc. announced today that results from investigator-sponsored studies on Kuvan (sapropterin dihydrochloride) are being presented at the 2010 Annual Symposium of the Society...
-
Aug 30, 2010
BioMarin Pharmaceutical Inc. announced today that it has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for BMN-701, a novel fusion of insulin-like growth factor...
-
Aug 17, 2010High Affinity ZC-701 Fusion Enzyme Replacement Therapy Demonstrates Superior Potency and Efficacy to Myozyme in Nonclinical Studies Phase I/II Clinical Study In Late Onset Pompe Expected to Start in Q1 2011 Conference Call and Webcast to Be Held Today at 5:00 p.m. ET
BioMarin Pharmaceutical Inc. announced today that it has acquired ZyStor Therapeutics, Inc. (ZyStor), a privately-held biotechnology company developing enzyme replacement therapies (ERT) for the...
-
Aug 17, 2010
BioMarin Pharmaceutical Inc. announced today that the first subject has initiated treatment in a Phase 3b study (PKU-016) to evaluate the effects of Kuvan (sapropterin dihydrochloride) on...
-
Aug 2, 2010R&D Pipeline Advancing Rapidly; Core Products Revenue In-Line Despite Challenging Economic Climate Firdapse Launch Delay Contributes to Reduction in Guidance Conference Call and Webcast to Be Held Today at 5:00 p.m. ET
Financial Highlights ($ in millions, except per share data, unaudited) Item Q2 2010 Q2 2009 Comparison Total BioMarin Revenue $92.0 11.1% increase Total Net Product Revenue $90.6 11.2% increase...
-
Aug 2, 2010Conference Call and Webcast to Be Held Today at 5:00 p.m. ET
BioMarin Pharmaceutical Inc. announced today an update in the Phase 2 clinical study of PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase) for the treatment of phenylketonuria (PKU). Data...
